Literature DB >> 19037043

Cytologic detection of cervical abnormalities using liquid-based compared with conventional cytology: a randomized controlled trial.

Albertus G Siebers1, Paul J J M Klinkhamer, Marc Arbyn, Amidu O Raifu, Leon F A G Massuger, Johan Bulten.   

Abstract

OBJECTIVE: To compare test positivity rates of liquid-based and conventional cytology.
METHODS: This study was a cluster randomized controlled trial with family practice as the unit of randomization, performed within the Dutch national cervical screening program. Women aged 30-60 years (n=89,784) recruited from 246 family practices were included. One-hundred twenty-two practices (49,222 individuals) were randomly assigned to the experimental arm, and 124 practices (40,562 participants), to the conventional arm. Inclusion was performed during a 3-year period between April 2003 and July 2006. Cytologic test positivity rates of liquid-based compared with conventional cytology was compared in terms of crude and adjusted odds ratios, applying a per-protocol analysis.
RESULTS: Crude ratios of the odds of test positivity rates of liquid-based compared with conventional cytology for atypical squamous cells of undetermined significance or more severe, low-grade squamous intraepithelial lesion or more severe, and high-grade squamous intraepithelial lesion or more severe were 0.95 (95% confidence interval [CI] 0.82-1.10), 1.00 (95% CI 0.83-1.20), and 0.97 (95% CI 0.77-1.22), respectively. Liquid-based cytology resulted in fewer unsatisfactory tests (odds ratio 0.30, 95% CI 0.23-0.38). The results did not change when the odds ratios were adjusted for age, study site, study period, and urbanization level. Of 128 women screened with liquid-based cytology, one unsatisfactory preparation is avoided.
CONCLUSION: This study found no statistically significant difference in cytologic test positivity rates between liquid-based and conventional cytology. However, liquid-based cytology resulted in significantly fewer unsatisfactory tests. CLINICAL TRIAL REGISTRATION: Nederlands Trial Register, www.trialregister.nl, NTR1032 LEVEL OF EVIDENCE: I.

Entities:  

Mesh:

Year:  2008        PMID: 19037043     DOI: 10.1097/AOG.0b013e31818c2b20

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  9 in total

1.  Age-specific patterns of unsatisfactory results for conventional Pap smears and liquid-based cytology: data from two randomised clinical trials.

Authors:  P E Castle; J Bulten; M Confortini; P Klinkhamer; A Pellegrini; A G Siebers; G Ronco; M Arbyn
Journal:  BJOG       Date:  2010-08       Impact factor: 6.531

2.  Method for preservation of DNA stability of liquid-based cytology specimens from a lung adenocarcinoma cell line.

Authors:  Yukiko Matsuo; Kazuya Yamashita; Tsutomu Yoshida; Yukitoshi Satoh
Journal:  Virchows Arch       Date:  2020-08-31       Impact factor: 4.064

Review 3.  How to evaluate emerging technologies in cervical cancer screening?

Authors:  Marc Arbyn; Guglielmo Ronco; Jack Cuzick; Nicolas Wentzensen; Philip E Castle
Journal:  Int J Cancer       Date:  2009-12-01       Impact factor: 7.396

4.  Can LBC Completely Replace Conventional Pap Smear in Developing Countries.

Authors:  Vasundhara Kamineni; Priti Nair; Ashok Deshpande
Journal:  J Obstet Gynaecol India       Date:  2018-05-18

5.  Unsatisfactory rates vary between cervical cytology samples prepared using ThinPrep and SurePath platforms: a review and meta-analysis.

Authors:  Daniel Fontaine; Nadira Narine; Christopher Naugler
Journal:  BMJ Open       Date:  2012-04-13       Impact factor: 2.692

6.  A comparison of liquid-based cytology with conventional Papanicolaou smears in cervical dysplasia diagnosis.

Authors:  Fatemeh Haghighi; Nahid Ghanbarzadeh; Marziee Ataee; Gholamreza Sharifzadeh; Javid Shahbazi Mojarrad; Fatemeh Najafi-Semnani
Journal:  Adv Biomed Res       Date:  2016-10-26

7.  Cervical cancer incidence after normal cytological sample in routine screening using SurePath, ThinPrep, and conventional cytology: population based study.

Authors:  Kirsten Rozemeijer; Steffie K Naber; Corine Penning; Lucy I H Overbeek; Caspar W N Looman; Inge M C M de Kok; Suzette M Matthijsse; Matejka Rebolj; Folkert J van Kemenade; Marjolein van Ballegooijen
Journal:  BMJ       Date:  2017-02-14

8.  Comparing SurePath, ThinPrep, and conventional cytology as primary test method: SurePath is associated with increased CIN II+ detection rates.

Authors:  Kirsten Rozemeijer; Corine Penning; Albert G Siebers; Steffie K Naber; Suzette M Matthijsse; Marjolein van Ballegooijen; Folkert J van Kemenade; Inge M C M de Kok
Journal:  Cancer Causes Control       Date:  2015-10-12       Impact factor: 2.506

9.  Increased Risk of High-grade Cervical Neoplasia in Women with Inflammatory Bowel Disease: A Case-controlled Cohort Study.

Authors:  R L Goetgebuer; J E Kreijne; C A Aitken; G Dijkstra; F Hoentjen; N K de Boer; B Oldenburg; A E van der Meulen; C I J Ponsioen; M J Pierik; F J van Kemenade; I M C M de Kok; A G Siebers; J Manniën; C J van der Woude; A C de Vries
Journal:  J Crohns Colitis       Date:  2021-09-25       Impact factor: 9.071

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.